Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based clinical-stage biotechnology company, announced on Thursday that it has added Sanjay Juneja, MD to its Cancer Business Advisory Board.
Dr Juneja, a board-certified haematologist and medical oncologist, is presently practicing in Baton Rouge, Louisiana. He has served on the White House Leaders in Social Media roundtable and has been featured by The Washington Post, CNBC, PBS, and WebMD, among many others. He serves as an editorial board member for the peer-reviewed research journal AI in Precision Oncology, and as a contributor to Entrepreneur Magazine.
Anixa chairman and CEO Dr Amit Kumar, said, 'Dr Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations. His influence has earned him invitations to help shape healthcare policy, and, most importantly, his public voice empowers cancer patients with knowledge, support, and hope. We anticipate that Sanjay's rapidly growing national profile will aid in educating the cancer community about the novelty of our vaccines and therapeutics. His broad reach will be beneficial to Anixa as we advance our programs, including enrolment and site recruitment for our current and upcoming clinical trials.'
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
INOVIO names new chief commercial officer
Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial
Bavarian Nordic files for chikungunya vaccine approval in Europe
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
Philippine lawmakers call for probe into secret US propaganda operation
Gavi seeking funding to immunise poorest children
Sanofi partners with Biovac to manufacture polio vaccines in Africa